Notably, this regulatory mechanism is active regardless of androgen receptor (AR) status, expanding its therapeutic relevance to castration-resistant (CRPC) and AR-null PCa subtypes, for which treatment options remain limited [17,20,21,22,23]. Here, AR is linked to posterior cortical atrophy.